Overview

Pharmacokinetic Study on the Addition of Aprepitant to Cisplatin - Etoposide Treatment in Lung Cancer Patients

Status:
Terminated
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether aprepitant can be used in the Cisplatin - Etoposide chemotherapeutic regimen.
Phase:
Phase 4
Details
Lead Sponsor:
Radboud University
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Aprepitant
BB 1101
Cisplatin
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Etoposide
Fosaprepitant
Ondansetron